				1			APPLICATION NO.	•				
		or perenewa	D DV 455:	The second	5914-080-999 09/305,084			4				
	LIST	OF REFERENCES CITE	/ \ \ T		APPLICANT							
		(Use several sheets if i	necesser(J)	\choos \(\choos \)	Schneider et al.			<u>-</u>				
			AUA	1 9 1999	FILING DATE		1648	648)			
AUG 1 9 1999 5 05/04/99 1642												
*EXAMINER DOCUMENT NUMBER DATE RADEN NAME CLASS SUBCLASS FILING DATE E APPROPRIATE												
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		OPRIATE			
awn	AA	4,190,496	02/26/80	Rubenstein et	al.							
	AB	4,376,110	03/08/83_	David et al.		<u> </u>						
	AC	4,946,778	08/07/90	Ladner et al.								
	AD	4,980,286	12/25/90	Morgan et al.				<u> </u>				
	AE	5,082,838	01/21/92	Naka et al.								
\Box	AF	5,114,918	05/19/92	Ishikawa et al.	;							
aul	AG	5,187,195	02/16/93	Oohata et al.								
1	АН	5,198,548	03/30/93	Beylin et al.								
	AI	5,208,243	05/04/93	Peglion et al.								
	AJ	5,240,910	08/31/93	Lam et al.								
	AK	5,248,807	09/28/93	 Fujimoto et al.								
	AL	5,270,313	12/14/93	Burri et al.			_					
	АМ	5,334,598	08/02/94	Bagley et al.								
	AN	5,352,659	10/04/94	Wakimasu et a	al.							
	/ AO_	5,352,800	10/04/94	Bills et al.								
	AP	5,382,569	01/17/95	Cody et al.								
	ΑQ	5,464,853	11/07/95	Chan et al.			_		_			
V	AR	5,585,089	12/17/96	Queen et al.								
			FORE	IGN PATENT DOC	UMENTS							
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS	SLATION			
								YES	NO			
amb	AS	A1 0 436 189	07/10/91	EP								
-	AT	A1 0 496 452	07/29/92	EP			_					
	AU	A1 0 558 258	09/01/93	EP		<u> </u>						
	AV	A1 0 569 193	11/10/93	EP								
	AW	2,067,288	10/26/92	CA								
	JAX	2,071,193	12/14/92	CA								
	AY	WO 92/06180	04/16/92	PCT		U	_					
	AZ	WO 92/20316	11/26/92	PCT								
7	/ _{BA}	WO 92/22635	12/23/92	PCT								

·	T -		1				· ·	1
amer	ВС	WO 93/14188	07/22/93	PCT				+
-1/	BD	WO 93/20221	10/14/93	PCT PE	_			<u> </u>
<u></u>	BE	WO 94/27979	12/08/94	PCT O	<u>~~</u>		-	\downarrow
			<u> </u>	AUG 1 9 1	99 <u>C</u>		<u> </u>	4
				3	<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>			\perp
<u> </u>		OTHER REFE	RENCES (Inclu	uding Author, THE TRADE	Pertinent Pag	es, Etc.)		
amer	BF	Albino et al., 1991,	Cancer Res.,	51 :4815-4820	,			
 	BG	Arai et al., 1990, N	ature, 348:73	30-732				
	вн	Becker et al., 1992,	Oncogene, 7	7:2303-2313				
	ВІ	Benigni et al., 1993	, Kidney Int.,	44:440-444				
	BJ	Bird, 1988, Science	, 242 :423-42	26				
	ВК	Bolger et al., 1991,	Can. J. Phys	iol. Pharmacol., 69: 4	06-413		···	
	BL	Brabant, et al., 199	3, Cancer Res	earch, 53 : 4987-499	3			
1.	вм	Brooks et al., 1991,	Eur. J. Pharm	n. 194 :115-117				
\\\\	BN	Calabresi P. and Ch Pergamon Press, 8t			he Pharmacolo	gical Basis of	f Therape	ut
V	во	Calabresi P. and Ch Pergamon Press, 8t			ne Pharmacolo	gical Basis of	f Therape	ut
amh	BP	Clozel et al., 1993,	Nature 365 :7	59-761		-		
	во	Cody et al., 1993, I	Med. Chem. R	es. 3 :154-162				
	BR	Daniel <i>et al.</i> , 1997,	BioEssays, 19	0(10): 883-891				
	BS	Doherty, 1992, J.	Med. Chem.,	35 :1493-1508		····		
_//	вт	Dorudi, et al., 1993	, American J	ournal of Pathology, 1	12 :981-986			
\'	ВU	Dotto et al., 1989,	J. Cell Biol.,	109 :3115-3128				
·\V	BV	Fujimoto et al., 199	2, FEBS Lett.,	305:41-44				
amh	вw	Furchgott and Zawa	idski, 1980, N	lature, 288:373-376				
	вх	Gamallo, et al., 199	3, American	Journal of Pathology,	142 :987-993		Sheet 2 of	
	BY	Greenspan & Bona,	1993, FASEB	J., 7(5):437-444		- -		
<u> </u>	BZ	Halaban et al., 199	2, Oncogene,	7 :2195-2206	- · · · · · · · · · · · · · · · · · · ·			
	СА	Halaban, 1991, Car	cer Metastasi	s Rev., 10:129-140				
	СВ	Herren, et al., 1998	, Mol. Biol. C	Cell., 9:1589-601				
	СС	Hsu, et al., 1996,	J. Investig. De	ermatol. Symp. Proc.,	1:188-94			
/	CD	Hunt <i>et al.</i> , 1991, <i>l</i>	Biorganic and I	Medic. Chem. Lett., 1:	33-38			
$\overline{}$	CE	Imokawa, et al., 19	92, <i>J. Biol. Cl</i>	hem., 267 ;24675-80	<u> </u>			
1	CF	Imokawa, <i>et al.,</i> 19	96, <i>Biochem</i> .	J., 314:305-12				
any	CG	Ishikawa et al., 199	2, J.M d. Ch	em., 35 :2139-2142				
$\bot \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \!$	СН	Kanno et al., 1990,	J. Amer. Me	d. Assoc. , 264 :2868				
W	СІ	Karaki <i>et al.</i> , 1994,	Biochem. Bio	onhys Res Commun	205-168-173			

1		The second secon
ama	CL	Köck et al., 1991, Cancer Treat. Res., 54:41-66 Kohzuma et al. 1994 Neuroreport, 5:2653-2656
	СМ	Aut 1 8 1000 Aut
	CN	Koller & Smithies, 1989, Proc. Natl. Acad. Sci. USA, 86:\$932-8935
	со	Krutmann et al., 1992, J. Invest. Dermatol., 98:923-928
	СР	Lam, K.S. et al., 1991, Nature, 354 :82-84
	CQ	Lu et al., 1992, Proc. Natl. Acad. Sci., 89 :9215-9219
	CR	Marsault, et al., 1991, Biochem. Biophys. Res. Commun., 179:1408-13
V	cs	Miyata et al., 1992, J. Antibiot., 45 :74-8;
auch	СТ	Miyata et al., 1992, J. Antibiot., 45:1041-1046
	CU	Miyata et al., 1992 J. Antibiot, 45 :1029-1040
	cv	Moll, et al., 1993, American Journal of Pathology, 143: 1731-1742
	cw	Morel et al., 1989, Eur. J. Pharmacol., 167 : 427-428
	СХ	Nakajima et al., 1991, J. Antibiot., 44 :1348-1356
	CY	Nishikibe et al., 1993, Life Sci., 52 :717-724
V	CZ	Nishiyama et al., 1995, Jpn.J. Pharmacol. Japan, 69(4):391-398
ann	DA	Nissonoff, 1991, J. Immunol., 147(8):2429-2438
	DB	Oka, et al.,1993, Cancer Research, 53 : 1696-1701
	DC	Okazawa, et al., 1998, J. Biol. Chem., 273:12584-92
	DD	O∯hashi et al., 1992, J. Antibiot, 45 :1684-1685
	DE	Otto, et al., 1994, Cancer Research, 54 : 3120-3123
	DF	Palmer et al., 1987, Nature, 327 :524-526
	DG	Pignatelli, et al., Journal of Pathology, 1994, 174:243-248
	DH	Pizarro, et al. 1994, Br. J. Cancer, 69(1) :157-162
	⁷ DI	Rodeck et al., 1991, J. Invest. Dermatol., 97:20-26
91	DJ	Rodeck and Herlyn, 1991, Cancer Metastasis Rev., 10:89-101
Y	DK	Rosenfeld et al., 1992, Cell, 68 :143-155
ams	DL	Saida et al., 1989, J. Biol. Chem., 264 :14613-14616
	DM	Saito et al. (1990) Hypertension, 15:734-738;
	DN	Sakurai et al. (1990) Nature, 348 :732-735
	DO	Saunders Company, Philadelphia, pages: 340-341 Cellular and Molecular Immunology", 1991 eds., Abbas A. K., Lichtman, A. H., Pober, J. S.;
	/ DP	Scaffidi et al., 1999, J. Biol. Chem., 3:1541-1548
	DQ	Schipper, et al., 1991, Cancer Research, 51:6328-6337
	DR	Shibata et al., 1996, Peptide Chemistry 1995, Proc. of the 33rd Symp. on Peptide Chem., Sapporo, Japan, page 281-284
	DS	Shih et al., 1994, <i>Am. J. Pathol.</i> , 145 :837-45
MI	DT	Shimoyama et al., 1992, Cancer Res., 52:5770-5774
W	DU	Songyang, Z. et al., 1993, Cell, 72:767-778

		Sheet 4
amh	DW	Tanaka et al., 1994, Mol. Pharmacol., 45:724-730
	DX	Tang, et al., 1994, <i>J. Cell. Sci.</i> , 107 :983-92
	DY	Thornberry, et al., 1998, Science, 261 :1312-8
	DZ	Tohma, et al., 1992, Cancer Research, 52: 1981-1987
	EA	Tomita et al., 1989, N. Engl. J. Med. 321 :1127
	EB	Umbas, et al., Cancer Research, 1992, 52 :5104-5109
V _L	EC	Urade et al.,1992, FEBS Lett., 311 :12-16 一
any	ED	Valyi-Nagy et al., 1993, <i>Lab Invest.,</i> 69 :152-9
	EE	Vanhoutte et al., 1986, Annual Rev. Physiol., 48: 307-320
	EF	Vermeulen, et al., 1996, <i>Pathol. Res. Pract.</i> , 192 : 694-707
	EG	von Geldern et al., 1991, Peptide Res., 4: 32-35
	EH	Wu and Wu, 1987, J. Biol. Chem., 262 :4429-4432
W	EI	Yamanishi et al., 1992, Cancer Res., 52 :5024-5029
V	EJ	Zijlstra et al., 1989, Nature, 342 :435-438
	<u> </u>	OIPE
		r / %
	1	AUG 1 9 1999 E
		TRADEMARKS TRADEMARKS
		W THAUCE
	 	÷
	-	
	+	
		
<u> </u>	-	
	-	
	-	
		·
		<u> </u>
	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

1

EL

		* *	
			the -
EXAMINER	anotheris	DATE CONSIDERED TO BRUSHIN 20.	2001

Kikuchi et al., 1996, Biochem. Biophys. Res. Commun., 219:734-739

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FEB 13 2001

TECH CENTER 1600/2900